C.M. Bidwell & Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

C.M. Bidwell & Associates’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-361	Closed	-$2.74K	–	489
2025 Q3	$2.74K	Sell	361 -7,390	-95%	-$61.5K	﹤0.01%	381
2025 Q2	$69.4K	Buy	+7,751	New	+$72.2K	0.04%	202
2021 Q4	–	Sell	-14,005	Closed	-$201K	–	554
2021 Q3	$201K	Hold	14,005	–	–	0.13%	147
2021 Q2	$221K	Buy	+14,005	New	+$190K	0.14%	132

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

C.M. Bidwell & Associates's BCRX Position: Q4 2025 in Review

C.M. Bidwell & Associates sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 361 shares — an estimated $2.74K sold.

C.M. Bidwell & Associates first reported a position in BCRX in Q2 2021 and held it in 4 quarters. The position peaked at $221K in Q2 2021. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

C.M. Bidwell & Associates reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
C.M. Bidwell & Associates sold 361 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $2.74K.
C.M. Bidwell & Associates first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 4 quarters.
C.M. Bidwell & Associates's BioCryst Pharmaceuticals position peaked at $221K in Q2 2021.
272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2025, filed 13 Feb 2026.